Teva Pharmaceuticals shares are trading higher after Piper Sandler upgraded the stock from Neutral to Overweight and raised its price target from $12 to $19.
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceuticals' stock price increased following an upgrade by Piper Sandler from Neutral to Overweight, with a raised price target from $12 to $19.
February 12, 2024 | 1:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Teva Pharmaceuticals' stock price is likely to experience a short-term increase following the upgrade by Piper Sandler from Neutral to Overweight and a significant raise in the price target from $12 to $19.
Analyst upgrades, especially from neutral to overweight, typically lead to a positive market reaction as they suggest a strong bullish outlook on the stock. The substantial increase in the price target from $12 to $19 further underscores the analyst's confidence in the stock's potential, likely leading to increased investor interest and a short-term price increase.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100